Optimizing ALK-TKI Sequencing and Neurological Outcomes
Panelists discuss the circumstances under which they would consider switching patients on different first-line treatments to lorlatinib and outline approaches for CNS surveillance and management in ALK-positive patients.
- For patients already on different first-line treatment, under what circumstances would you consider switching them to lorlatinib?
- How should we approach CNS surveillance and management in ALK-positive patients?
Related Content:
